» Articles » PMID: 36386817

Immunogenic Cell Death Mediation Patterns Reveal Novel Paradigm for Characterizing the Immune Microenvironment and Immunotherapeutic Responses in Bladder Cancer

Overview
Journal Front Genet
Date 2022 Nov 17
PMID 36386817
Authors
Affiliations
Soon will be listed here.
Abstract

Immunogenic cell death (ICD) plays an important role in several malignancies. However, the role of ICD-mediated patterns in bladder cancer (BCA) remains unknown. For assessing the ICD-mediated patterns based on the expression of IRGs, 4 large BCA cohorts were obtained. The ICD-mediated patterns of individual samples were quantified as an ICD score by principal component analysis. The correlations of the ICD-mediated patterns with the tumor immune microenvironment (TIME) and responses to immunotherapy were comprehensively evaluated. The IRGs with predictive prognostic values were further validated by loss of function assays. Two distinct ICD-mediated patterns were established, showing distinct clinical features and immune microenvironment features. Although ICD cluster A was associated with a poor prognosis with a high ICD score, it showed an immune activation state with a more favorable response to immunotherapy and treatment that induced ICD. The ICD-related gene, CALR, was significantly upregulated in the T24 BCA cell line relative to the control SV-HUC-1 cells. Knocking down CALR suppressed T24 cell viability and caused ER stress. We identified the existence of distinct ICD-mediated patterns in BCA closely associated with the remodeling of the TIME. Further in-depth examination of ICD-related features is warranted to obtain a broader prospect for therapeutic innovations and improved prognosis of BCA.

Citing Articles

Exploring the dual role of endoplasmic reticulum stress in urological cancers: Implications for tumor progression and cell death interactions.

Farahani N, Alimohammadi M, Raei M, Nabavi N, Aref A, Hushmandi K J Cell Commun Signal. 2024; 18(4):e12054.

PMID: 39691874 PMC: 11647052. DOI: 10.1002/ccs3.12054.


Immunogenic cell death: A new strategy to enhancing cancer immunotherapy.

Dou L, Fang Y, Yang H, Ai G, Shen N Hum Vaccin Immunother. 2024; 20(1):2437918.

PMID: 39655738 PMC: 11639453. DOI: 10.1080/21645515.2024.2437918.


Prognostic Significance and Immune Landscape of an Efferocytosis-Related Gene Signature in Bladder Cancer.

Zheng F, Wang Z, Dong Q, Li S, Xiong S, Yuan Y Biochem Genet. 2024; .

PMID: 39313721 DOI: 10.1007/s10528-024-10924-0.


Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot.

Han Y, Tian X, Zhai J, Zhang Z Front Cell Dev Biol. 2024; 12:1363121.

PMID: 38774648 PMC: 11106383. DOI: 10.3389/fcell.2024.1363121.


Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.

Peng M, Chu X, Peng Y, Li D, Zhang Z, Wang W MedComm (2020). 2023; 4(6):e455.

PMID: 38107059 PMC: 10724512. DOI: 10.1002/mco2.455.


References
1.
Huang R, Jalil J, Economou J, Chmielowski B, Koya R, Mok S . CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011; 17(12):4101-9. PMC: 3117971. DOI: 10.1158/1078-0432.CCR-11-0407. View

2.
Bowers J, Nelson M, Majchrzak K, Bailey S, Rohrer B, Kaiser A . Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight. 2017; 2(5):e90772. PMC: 5333954. DOI: 10.1172/jci.insight.90772. View

3.
Nikolos F, Hayashi K, Hoi X, Alonzo M, Mo Q, Kasabyan A . Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nat Commun. 2022; 13(1):1487. PMC: 8960844. DOI: 10.1038/s41467-022-29026-9. View

4.
Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P . Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020; 11(11):1013. PMC: 7691519. DOI: 10.1038/s41419-020-03221-2. View

5.
Morad G, Helmink B, Sharma P, Wargo J . Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021; 184(21):5309-5337. PMC: 8767569. DOI: 10.1016/j.cell.2021.09.020. View